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Abstract
Background: This study aimed at investigating the effect of a resistance exercise intervention on the interstitial
muscle levels of pro-inflammatory cytokines in fibromyalgia (FMS) and healthy controls (CON).
Methods: Twenty-four female patients with FMS (54 ± 8 years) and 27 female CON (54 ± 9 years) were subjected to
intramuscular microdialysis of the most painful vastus lateralis muscle before and after 15 weeks of progressive
resistance exercise twice per week. Baseline dialysates were sampled in the resting muscle 140 min after insertion
of the microdialysis catheter. The participants then performed repetitive dynamic contractions (knee extension) for
20 min, followed by 60 min rest. Pain intensity was assessed with a 0–100 mm visual analogue scale (VAS), and
fatigue was assessed with Borg’s RPE throughout microdialysis. Dialysates were sampled every 20 min and analyzed
with Luminex for interleukin (IL)-1β, tumor necrosis factor (TNF) alpha, IL-6, and IL-8.
Results: At both sessions and for both groups the dynamic contractions increased pain (P < 0.012) and fatigue (P <
0.001). The levels of TNF were lower in the FMS group than the CON group at both sessions (P < 0.05), but none of
the other cytokines differed between the groups. IL-6 and IL-8 increased after the dynamic contractions in both
groups (P < 0.010), while TNF increased only in CON (P < 0.05) and IL-1β did not change. Overall pain intensity was
reduced after the 15 weeks of resistance exercise in FMS (P < 0.05), but there was no changes in fatigue or cytokine
levels.
Conclusion: Progressive resistance exercise for 15 weeks did not affect the interstitial levels of IL-1β, TNF, IL-6, and
IL-8 in the vastus lateralis muscle of FMS patients or CON.
Trial registration: Clinicaltrials.gov NCT01226784, registered 21 October 2010.
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Background
Chronic pain is a huge health problem worldwide with
immense costs for the society in terms of lost productiv-
ity, health care visits, medication, and so forth, but also
for the individual in terms of social burden and negative
impact on quality of life [1]. In the USA, as many as 100
million adults suffer from chronic pain with an
estimated cost of around US$600 billion [1, 2]. In
Europe, almost 20 % of the population report pain of
moderate to severe intensity with at least a 6-month
duration, with an estimated yearly cost of €3.4 billion
[3]. Musculoskeletal pain is by far the most frequent
type of chronic pain, encompassing about 90 % of all
chronic pain [3, 4].
Fibromyalgia syndrome (FMS) is a musculoskeletal
pain disorder that mainly affects women and is charac-
terized by widespread pain and tenderness, stiffness, fa-
tigue, sleep disturbances, and cognitive dysfunction [5].
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Exercise intolerance is regarded a key symptom in FMS
[6] and even normal household chores often lead to
worsening of symptoms. In healthy subjects, exercise
usually increases pressure pain thresholds (PPTs) due to
activation of endogenous analgesia, but in FMS patients
muscle contractions reduce PPTs [6–8]. In spite of this,
physical exercises of moderate intensity are included in
the multimodal intervention programs for the manage-
ment of FMS. Indeed, several studies have shown benefi-
cial effects of regular exercises in FMS [9, 10]. Further,
exercise of moderate intensity increased functional aer-
obic capacity and improved activities of daily living in
FMS [11] and a recent systematic review reported posi-
tive results of diverse exercise interventions on pain,
multidimensional function, and self-reported physical
function [12].
Despite its large impact on society, the mechanisms
behind FMS are not well known. A biopsychosocial
model is mostly suggested, including both biological and
psychological factors. With respect to biological factors,
the common belief has for some time been that central
alterations in pain processing are of greatest importance
and that peripheral input plays a minor or no role [13].
However, it was recently suggested that peripheral
mechanisms, such as temporal summation, due to nor-
mal muscle work may be important to drive pain hyper-
sensibility [14–16]. This may be enough to cause
repeated release of nociceptive and inflammatory sub-
stances causing long-lasting peripheral and central
sensitization. In support of this is increasing evidence
over the past years that the interstitial levels of many
algesic and metabolic substances are elevated in painful
muscles of patients with local or regional chronic myal-
gia [17]. However, relatively few studies have investigated
interstitial muscle levels of nociceptive substances in
FMS. An early study showed that the release of sero-
tonin in the masseter muscle was elevated in response to
trauma in FMS [18]. More recently, Gerdle et al. showed
that the interstitial levels of lactate and pyruvate in the
trapezius muscle were elevated in patients with FMS
[19, 20]. Patients with chronic widespread pain also
seem to have difficulties in recruiting antinociceptive
substances, such as endocannabinoids, in response to
contractions [21]. An increased release of nociceptive
substances in combination with reduced release of anti-
nociceptive substances may therefore participate in pain
amplification.
Cytokines are small proteins that are produced in many
diverse cells of the immune system, such as monocytes,
lymphocytes, and mast cells, but also in endothelial cells
and fibroblasts [22]. They are involved in cell signaling
and play a critical role in the immune system. Many of the
symptoms seen in inflammatory conditions that are gener-
ally attributed to central release of cytokines are similar to
those seen in FMS [22]. For example, animal research sug-
gests a role for interleukin (IL)-1β in fatigue and hyper-
algesia, and tumor necrosis factor (TNF) beta and IL-6
can trigger daytime sleepiness and pain but also elicit cog-
nitive dysfunction [22–25]. This may imply that central re-
lease of cytokines may be involved in FMS. Indeed, central
inflammation was proposed in its pathophysiology based
on findings of increased cerebrospinal fluid (CSF) levels of
IL-8 in FMS [26].
It is well-known that short-term exercise increases
some cytokine levels, especially IL-6 [27]. Some studies
have investigated circulating cytokine levels in FMS and
reported increased levels of IL-6, IL-8, and TNF, but
a blunted response of IL-10 to short-term exercises
[6, 28]. We have recently investigated the effect of dy-
namic muscle contractions on interstitial muscle release
of pro-inflammatory cytokines in FMS [29]. We found
that TNF was higher in pain-free controls than in FMS
and increased in response to contractions only in controls,
while IL-6 and IL-8 did not differ between groups and in-
creased in both groups. However, muscle and plasma
cytokine levels were not related.
Interestingly, while short-term exercise seems to in-
crease cytokine levels, a few recent reports have shown
reductions in pro-inflammatory cytokine levels in re-
sponse to long-term exercise in FMS. A systematic re-
view based on nine articles concluded that, despite
minimal evidence, exercise interventions might act as an
anti-inflammatory treatment in FMS patients by redu-
cing circulating IL-6 and IL-8 levels [30]. Further, in
FMS patients subjected to 15 weeks of Nordic walking,
changes of insulin growth factor-1 (IGF-1) correlated
positively to changes of pain threshold, indicating a pos-
sible beneficial role for IGF-1 during exercise [31].
However, no previous study has investigated long-term
effects on muscle levels of cytokines in response to
physical exercise in FMS. Therefore, this study aimed at
investigating the interstitial muscle release of pro-
inflammatory cytokines in patients with FMS before and
after a resistance exercise intervention. The hypothesis
was that if muscle release of pro-inflammatory cytokines
was elevated in FMS, they would be normalized after
15 weeks of resistance exercise.
Methods
Participants
Female patients with FMS and age-matched healthy
women (CON) were included. The subjects participated
in a randomized controlled multicenter trial regarding
the effects of progressive resistance exercise or relax-
ation exercise on FMS symptoms (Clinicaltrials.gov
NCTO1226784, 21 October 2010). The enrollment
process for the patients has been described in detail pre-
viously [32, 33].
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Microdialysis was performed in a subgroup of patients
and CON. The first 10 patients at each of the three par-
ticipating centers (12 at one site) who were randomized to
resistance exercise and volunteered to also participate in
microdialysis before and after the exercise were included.
For CON, healthy individuals in the multicenter center
study who were willing to participate in microdialysis and
resistance exercise were included (the same number as
FMS). They were matched to the FMS patients according
to age. In this study, data are reported for those subjects
who participated in both microdialysis sessions and for
whom complete microdialysis data were obtained at both
sessions. Two FMS patients and two CON of the included
64 participants dropped out from the study and addition-
ally six FMS patients and three CON were excluded due
to technical failure during microdialysis (e.g., crashed
catheters, so no fluid could be sampled). Thus, 24 FMS
patients and 27 CON participated.
Inclusion criteria for the patients were: 1) a diagnosis
of FMS according to the American College of Rheuma-
tology (ACR) 1990 [34] classification criteria; and 2) to
be of working age (20–65 years).
Inclusion criteria for the healthy controls were: 1) good
general health; 2) pain-free; and 3) age 20–65 years.
Exclusion criteria for both groups were: 1) high blood
pressure (>160/90 mmHg); 2) osteoarthritis in the hip or
knee; 3) other severe somatic or psychiatric disorders;
4) primary causes of pain other than FMS; 5) high con-
sumption of alcohol (audit >6); 6) participation in a re-
habilitation program within the past year; 7) regular
resistant exercise training or relaxation exercise training
more than twice a week; 8) inability to understand or
speak Swedish; and 9) not being able to refrain from non-
steroidal anti-inflammatory drugs (NSAIDs) for 1 week
and paracetamol, opioids, or hypnotics for 48 h prior to
microdialysis.
The participants were allowed to continue with their
other regular medication. As such, eight in the FMS
group used antidepressants (tricyclic antidepressants
(TCA), selective serotonin reuptake inhibitors (SSRI),
serotonin norepinephrine reuptake inhibitors (SNRI)),
one used gabapentin, and one used tramadol. Three
CON used antidepressants (SSRI).
Procedure
The participants were examined clinically by a physician
approximately 1 week before the first microdialysis ses-
sion. The examination also included a functional test of
physical capacity, the number of tender points, pressure
algometry, and a battery of questionnaires. The question-
naires included registrations of psychological distress and
quality of life. For all participants age (years), weight (kg),
height (m) and blood pressures (mmHg) were registered
and body mass index (BMI; kg/m2) was calculated.
Intramuscular microdialysis in the vastus lateralis
muscle of the most painful leg was performed during
220 min before and after the resistance exercise. Before
microdialysis, a venous blood sample (20 mL) was drawn
from the decubital vein for analysis of plasma cytokine
levels for comparison to interstitial levels, i.e., to see if
interstitial levels indicate local release. Both sessions in-
cluded 20 min of repetitive dynamic muscle contractions
of the leg during microdialysis.
Assessment of anxiety, depression, and quality of life
All participants completed a battery of questionnaires; of
these the validated Swedish versions of the Hospital
Anxiety and Depression Scale (HADS) to assess anxiety
and depression [35], and the Short-Form Health Survey
(SF36) to assess quality of life [36] were included as
background variables in this study. For a complete de-
scription of the HADS and SF36, see [37, 38]. From the
SF36 the physical (SF36-PSC) and mental (SF36-MSC)
summary components were calculated.
Physical capacity
Three tests were used for measurement of physical
capacity: maximal isometric elbow flexion force, max-
imal isometric knee extension, and a 6-min walk test
(6MWT). Maximal isometric elbow flexion force (kg)
was measured in both arms (one at a time) using a
dynamometer (Isobex®; Medical Device Solutions AG,
Oberburg, Switzerland) with the participant seated with-
out back support with legs stretched out in front. The
upper arm was aligned with the trunk and the elbow
was bent in 90° flexion. The maximum force obtained
during a period of 5 s was recorded [39].
Static knee extension force (N) was determined in
both legs using a dynamometer (Steve Strong®; Stig
Starke HBI, Göteborg, Sweden). The participants were
seated in a fixed position with back support and the
knee and hip in 90° of flexion and legs hanging freely. A
non-elastic strap was placed around the ankle and at-
tached to a pressure transducer with an amplifier. The
maximum force during a period of 5 s was recorded.
The instrument has been used in previous studies of
physical performance [40, 41].
For the 6MWT, the distance that the participant could
walk during six min in a standardized situation was reg-
istered [42].
Pressure algometry
Pressure pain thresholds (PPTs), defined as the mini-
mum pressure that elicited a pain response, were re-
corded bilaterally over four points in FMS in accordance
with the ACR 1990 criteria [34], i.e., the supraspinatus
muscle (at origins above the scapula spine near the med-
ial border), the lateral epicondyle (2 cm distal to the
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epicondyles), the gluteus maximus (in the upper outer
quadrants of the buttocks in the anterior fold of muscle),
and the inside of the knee (at the medial fat pad prox-
imal to the joint line). Each site was assessed only once
to avoid the risk of temporal summation and the same
order (as described above) was used for all participants
starting with the points on the right side. An electronic
algometer (Somedic Sales AB, Höör, Sweden) with a
blunt rubber tip of 1 cm2 and a pressure rate of approxi-
mately 50 kPa/s was used. Before the recordings, the sub-
jects were given instructions and the procedure was tested
over a site not included in the actual recordings. The alg-
ometer was held perpendicular to the skin at the site and
subjects were instructed to press the button when the sen-
sation of pressure changed to pain [43]. If the subject did
not press the button before 1500 kPa was reached, the ap-
plication of pressure was interrupted. The mean value of
all eight assessments for each subject was calculated and
used for further analysis as the individual’s PPT.
Assessments of pain and fatigue
Current pain intensity was assessed as overall pain and
pain for the most painful leg separately with a 0–
100 mm visual analogue scale (VAS), with the endpoints
0 = no pain and 100 = worst imaginable pain. The level
of fatigue was assessed with Borg’s 6-20 Ratings of
Perceived Exertion (Borg’s RPE) Scale [44].
Microdialysis
The participants were instructed to refrain from nicotine
(smoking) and caffeine (coffee or tea), but otherwise to eat
breakfast as usual in the morning on the day of microdialy-
sis. When they arrived at the clinical department it was en-
sured that they had not taken any NSAIDs during the last
7 days and no analgesics or sleeping pills in the last 48 h.
During microdialysis, the participants were resting in a
supine position on a bed, except during the 20 min of dy-
namic contractions, when they were sitting on the bed
with the back supported. The participants were allowed to
drink water and were served a cheese sandwich after 1.5 h
(during trauma phase, before the dynamic contractions).
Microdialysis was performed in the vastus lateralis
muscle of the most painful leg. If both legs had similar
pain levels, the muscle on the dominant side was
chosen. The same muscle was used at both sessions. The
skin overlying the muscle was anesthetized with 0.5 mL
lidocaine (Xyolocain 20 mg/mL). Two commercially
available microdialysis catheters (CMA Microdialysis
AB, Solna, Sweden), with 20 kDa (CMA 60) and
100 kDa (CMA 71) cut-off and membrane length
30 mm, were inserted into the muscle 3 cm apart in par-
allel to the muscle fibers in the mid-third part of the dis-
tance from the trochanter to the knee joint 5 min after
skin surface anesthesia. The 100 kDa catheter was used
for sampling cytokines in the present study and the
20 kDa for metabolites (data presented elsewhere). The
catheters were perfused with an infusion pump (CMA
107) set at 5 μL/h with a Ringer acetate solution
(Fresenius Kabi AB, Uppsala, Sweden) containing 3 mM
glucose, 0.5 mM lactate, 3.0 μM [14C]-lactate (specific ac-
tivity: 5.81 GBq/mmol; GE Healthcare, Buckinghamshire,
UK) as well as 0.3 μl/ml 3H2O (specific activity: 37 MBq/g;
PerkinElmer Life Sciences, Boston, USA).
Microdialysates were sampled every 20 min. The first
120 min of microdialysis was regarded as the trauma
phase and dialysates from this period were not analyzed.
The dialysate sample obtained at 140 min was regarded
as the baseline. The subjects then performed repetitive
dynamic contractions of the quadriceps muscle (knee ex-
tension) for 20 min. The participants were seated with
the legs outside the bed with the exercising leg slightly
bent and the foot and calf placed on a 40 cm Pilatus ball.
For participants with baseline pain level ≥40 mm on the
VAS in the exercising leg a knee angle of 15° was used
and for those with pain levels <40 mm on the VAS an
angle of 20° was used. The contralateral leg was bent 90°
with the foot supported. During the exercise the partici-
pants performed continuous knee extensions by slowly
lifting the leg until straight and then lowering it down
on the Pilatus ball, and then immediately lifting it again
without resting the leg on the ball. Each such cycle of
dynamic contractions took 5 s and was repeated for
20 min. After the contractions the subjects were asked
to lie down again on the bed and rest while the microdi-
alysis continued for 60 min.
Pain intensity (VAS) was assessed before insertion of the
microdialysis catheter and every 20 min (when changing
microdialysate vials) throughout the microdialysis session,
but every 5 min during the 20-min dynamic contractions.
Fatigue (Borg’s RPE) was assessed at baseline (140 min)
and every 5 min during the dynamic contractions.
Resistance exercise intervention
Previous studies have shown that low-intensity exercise,
adjusted to individual limitations, is feasible for most
FMS patients [45]. Progressive resistance exercise, twice
per week for 15 weeks under the supervision of specially
trained physical therapists, was used in this study. Each
session started with 10 min bicycling to warm up and
was then followed by 50 min resistance exercise. The ex-
ercise was initiated at low loads at 40 % of the maximum
voluntary capacity (MVC) and successively progressed
up to 70–80 % of MVC [46].
Handling of blood and microdialysate samples and
biochemical analyses
The blood samples were placed on ice and immediately
transported to the laboratory where they were centrifuged
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(1500 g) for 30 min. The plasma was pipetted into 1.5 mL
Eppendorf vials and frozen (–70 ° C) until analyses. All
microdialysate vials were weighed before and after micro-
dialysis to confirm that fluid recovery was adequate. After
visual inspection for blood contamination and weighing,
the samples were removed to Eppendorf tubes and imme-
diately frozen (–70 ° C).
Dialysate and plasma samples were analyzed for IL-1β,
TNF, IL-6, and IL-8 with Luminex technology (Bioplex,
Biorad Laboratories Inc., Hercules, CA, USA) using
standard kits with magnetic beads (dialysate: Millipore
HSCYTMAG-60SK; and plasma: HSTCMAG-28SK;
Merck KGaA, Darmstadt, Germany). The limits of de-
tection were: IL-1β <0.14 pg/mL; IL-6 < 0.13 pg/mL; IL-
8 < 0.13 pg/mL; and TNF <0.16 pg/mL. The intra-assay
percent coefficient of variation (%CV) was <10 % and
the inter-assay %CV <20 % for the analytes in both kits.
Statistics
Statistical analyses were made using Statistica version 12
(StatSoft Inc., Tulsa, OK, USA) and SigmaPlot version
13 (SysStat Inc., San José, CA, USA). The Kolmogorov-
Smirnov test was used to test for normality of the data.
None of the cytokines were normally distributed. An at-
tempt was therefore made to logarithmic (ln) transform
data, but data remained non-normally distributed. Most
other data were not measured on a continuous scale,
and non-parametric statistics were used for all analyses.
To analyze differences between cytokine levels, pain in-
tensities, and fatigue between sessions (before and after
the exercise intervention), the average of the cytokine
levels (cytokineAV) as well as pain (painAV) and fatigue
(fatigueAV) assessments obtained throughout the micro-
dialysis were used.
Descriptive data are presented as mean and standard
deviation (SD) or median and interquartile range (IQR).
Data before and after exercise were compared in each
group separately with Wilcoxon’s test or Friedman’s
ANOVA, whereas between-group comparisons were
made with independent t test or Mann Whitney U test.
Dunn’s test for multiple comparisons against a control
group (baseline) was used as a post-hoc test when the
Friedman test was significant. The Spearman correlation
test was used to analyze associations between cytokine
levels and pain as well as fatigue during microdialysis. A
significance level of P < 0.05 was used in all analyses.
Results
Dialysate cytokine levels
The cytokines levels are shown in Table 1 and Fig. 1. All
cytokines were detectable in the dialysates, but in vary-
ing frequencies with IL-1β being detectable in less than
50 % of samples, TNF in approximately 80 %, and IL-6
as well as IL-8 in more than 90 %. There were more
samples with detectable levels of TNF in CON than
FMS, but otherwise no group differences (Table 1). The
cytokine levels varied considerably between participants,
and IL-1β and TNF in general showed very low levels.
The cytokine levels further showed different profiles in
response to the dynamic contractions.
The levels of IL-1β did not change during dynamic
contractions in any group at any session.
IL-6 showed a similar profile in FMS and CON and
changed significantly during both sessions (Friedman
test: FMS, P < 0.008; CON, P < 0.001). In both sessions
and both groups IL-6 was significantly increased in the
sample obtained directly after the dynamic contractions
compared to baseline, then dropped in the next sample
whereafter it increased again and was significantly higher
compared to baseline in the last sample (220 min).
IL-8 showed a similar profile to IL-6. It increased dur-
ing dynamic contractions in both groups at both ses-
sions (Friedman test: P < 0.008 both groups), but with a
much less pronounced increase in FMS than CON, espe-
cially at the second session, i.e., after resistance exercise.
The post-hoc test showed that it was significantly in-
creased at most time points after the contractions com-
pared to baseline in both groups (Fig. 1).
TNF showed a somewhat different profile in FMS than
CON. Although it changed significantly in response to
dynamic contractions at both sessions in both groups
(Friedman test: FMS, P < 0.033; CON, P < 0.001), it was
significantly increased after dynamic contractions only
in FMS (Fig. 1).
When the cytokine levels were compared between ses-
sions, TNFAV was significantly lower in FMS than CON
at both sessions, but otherwise no group differences
were found in cytokine levels. None of the cytokines dif-
fered between sessions (Table 1).
Plasma cytokine levels
All cytokines were detectable in plasma in more than
70 % of samples and without group differences in fre-
quencies (Table 1). As with dialysate levels, there was a
large variation in plasma levels between participants.
The plasma level of IL-8 at baseline (before exercise)
was higher in FMS than CON, while plasma IL-6 was
higher in FMS than CON after exercise. The plasma
levels of IL-6 and IL-8 were lower than dialysate levels,
while plasma IL-1β and TNF levels were higher than di-
alysate levels. Plasma levels did not change after resist-
ance exercise in any of the groups (Table 1).
There were no significant correlations between plasma
and dialysate levels at any session in any group.
Pain intensity and fatigue
In both sessions the overall pain intensity and the pain
intensity in the most painful leg were, as expected,
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higher in FMS than in CON throughout the microdialy-
sis (data during the trauma phase not shown). There
were no significant changes in pain levels in the most
painful leg during the first 120 min of the trauma phase
in FMS at any session. In CON, the pain changed signifi-
cantly during the trauma phase at the second session,
i.e., after the resistance exercise (P = 0.011), but the post-
hoc test (Dunn’s test) could not detect any significant
difference between time points. During the 20 min of
dynamic contractions the pain intensity increased in
FMS in both sessions. The post-hoc test showed signifi-
cantly higher pain at 155 min (data not shown) and
160 min compared to 140 min at both sessions (Fig. 2).
There were no significant changes in CON during the
dynamic contractions.
The overall painAV during dynamic contractions had
decreased in FMS after the 15 weeks of resistance exer-
cise, but not the painAV in the exercising leg. There were
no significant differences in overall painAV or in the ex-
ercising leg in CON between sessions (Table 2).
The level of fatigue induced by the dynamic contractions
increased in both groups and in both sessions (Friedman
test: P < 0.001). The post-hoc test showed that it was higher
than at baseline at all time points in FMS before exercise
Table 1 Dialysate and plasma levels (pg/mL) of cytokines as well as frequency (%) of detectable samples in 24 patients with
fibromyalgia (FMS) and 27 healthy controls (CON) before and after 15 weeks of resistance exercise twice per week, as well as the
P value for within-group comparison (Wilcoxon test)
FMS P value CON P value
Before After Before After
IL-1β
Dialysate
Detectable 48 44 41 34
Level 0.10 (0.13) 0.05 (0.16) 0.522 0.06 (0.17) 0.01 (0.16) 0.479
Plasma
Detectable 70 83 89 96
Level 1.13 (3.55) 1.23 (1.86) 0.823 1.23 (1.40) 1.54 (1.33) 0.845
IL-6
Dialysate
Detectable 97 95 98 100
Level 81.1 (131.7) 100.4 (236.3) 0.540 156.4 (196.9) 107.0 (173.5) 1.000
Plasma
Detectable 91 100 96 96
Level 1.60 (1.48) 2.35 (2.14)* 0.831 1.31 (1.43) 1.41 (1.24) 0.556
IL-8
Dialysate
Detectable 95 91 98 99
Level 37.5 (75.6) 42.2 (71.6) 0.838 61.0 (101.4) 61.7 (58.0) 1.000
Plasma
Detectable 91 87 74 78
Level 1.66 (2.10)* 1.22 (3.19) 0.136 0.47 (1.61) 0.56 (1.11) 1.000
TNF
Dialysate
Detectable 67# 67# 93 94
Level 0.16 (0.18)* 0.19 (0.25)* 0.831 0.27 (0.23) 0.26 (0.17) 0.556
Plasma
Detectable 100 100 100 100
Level 4.27 (1.70) 3.79 (3.67) 0.831 3.72 (2.68) 3.56 (2.31) 1.000
The dialysate levels represent the average of 5 samples obtained during microdialysis (140-220 min), which included 20 min of dynamic exercise. Dialysate and
plasma levels are presented as median (interquartile range)
Between-group comparisons: *P < 0.05 (Mann-Whitney U test) #P < 0.001 (Chi square test)
IL interleukin, TNF tumor necrosis factor beta
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(P < 0.003) and at 150 min, 155 min, and 160 min after ex-
ercise (P < 0.001). In CON it was higher than baseline at
150 min, 155 min, and 160 min before exercise (P < 0.018)
and at 155 min and 160 min after exercise (P < 0.035).
The level of fatigueAV was higher in FMS compared to
CON at both sessions (P < 0.001). There were no signifi-
cant differences in fatigueAV between sessions in any
group (Table 2).
Fig. 1 Line and scatter plot showing the median (interquartile range) levels of cytokines during microdialysis in the vastus lateralis muscle of the
most painful leg in 24 patients with fibromyalgia (FMS) and 27 healthy controls (CON) before and after 15 weeks of resistance exercise twice per
week. a IL-1β, b IL-6, c IL-8, d TNF. Microdialysis was performed for 220 min. During the first 140 min the participant rested (data not shown),
whereafter they performed dynamic contractions of the leg (knee extension) for 20 min (EXC) followed by another 60 min of rest (recovery
phase). Samples were collected every 20 min and the dialysate sampled between 120–140 min was regarded as baseline (BL). *P < 0.05, both
sessions; #P < 0.05, only after resistance exercise. IL interleukin, TNF tumor necrosis factor beta
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Correlations between dialysate cytokines and pain
variables
In FMS there were moderately strong correlations be-
tween the baseline dialysate level of IL-6 and overall
pain intensity at baseline (rs = 0.48, P < 0.05, n = 24).
There were no significant correlations between baseline
pain and cytokine levels in CON. Neither were there any
correlations between cytokineAV levels and painAV/fatigueAV
levels in response to dynamic contractions, or between
changes of cytokine and pain/fatigue levels immediately
post-contractions in any group.
Muscle force and endurance
Table 3 shows muscle force before and after resistance
exercise. Before exercise the FMS group performed less
well on the 6MWT than CON. They also had less force
in the elbow flexors than CON, but there were no differ-
ences in knee extension force in the right and left legs
between groups. However, the knee extension force of
the most painful leg was lower in FMS than CON.
Both groups had a high participation rate in the resist-
ance exercise. In the FMS group the median (IQR) par-
ticipation rate was 95 % (111 %) and in CON 97 % (7 %).
Although both groups improved their muscle force and
endurance, intra-group comparison showed that only
the elbow flexion test in FMS reached statistical signifi-
cance (Table 3). As before the intervention, between-
groups comparison showed significant differences in the
6MWT, arm flexion force, and knee extension force of
the most painful leg, with lower values in FMS after the
exercise.
Background data
Background characteristics of the participants are pre-
sented in Table 4. There were no significant differences
in anthropometric data between groups. As could be ex-
pected, the overall pain intensity was higher and average
PPT for all sites combined were lower in FMS compared
to CON. Patients also had higher HAD depression and
HAD anxiety scores than CON, although they were in
the normal range (<10) in both groups. FMS further
Fig. 2 Line and scatter plot showing the median (interquartile
range) pain intensity (VAS 0–100 mm) during microdialysis in the
vastus lateralis muscle of the most painful leg in 24 patients with
fibromyalgia (FMS) and 27 healthy controls (CON) before (a) and
after (b) 15 weeks of resistance exercise twice per week.
Microdialysis was performed for 220 min. During the first 140 min
the participant rested (data not shown), whereafter they performed
dynamic contractions (EXC) of the leg (knee extension) for 20 min
followed by another 60 min of rest (RECOVERY). In FMS, but not in
CON, pain intensity increased during the dynamic contractions at
both sessions (Friedman test: P < 0.001). #P < 0.001 compared to
140 min (Dunn’s post-hoc test). VAS visual analogue scale
Table 2 Overall pain intensity, pain intensity in exercising leg, and fatigue in 24 patients with fibromyalgia (FMS) and 27 healthy
controls (CON) before and after 15 weeks of resistance exercise twice per week, as well as the P value for within-group comparison
(Wilcoxon test)
FMS P value CON P value
Before After Before After
Pain Overall (0–100) 53.5 (29.3) 50.0 (23.5) 0.025 0 (0) 0 (0) 0.723
Leg (0–100) 52.8 (24.4) 42.8 (32.7) 0.153 0 (1.5) 0 (0) 0.751
Fatigue Borg RPE 13.3 (2.7) 11.5 (4.0) 0.095 7.8 (2.8) 7.4 (3.0) 0.689
The figures represent the average of data sampled during microdialysis (140-220 min), which included 20 min of dynamic exercise. Data are presented as median
(interquartile range)
All variables differed significantly between groups at both sessions (P < 0.001; Mann-Whitney U test)
Bold italic figures denote significant differences
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scored lower on the SF-36-PSC and SF-36-MSC than
CON.
Discussion
This is the first study that has explored both the intersti-
tial muscle levels and systemic levels of cytokines in
FMS before and after a resistance exercise. Although
overall pain intensity had decreased and arm muscle
force improved after exercise, there were no significant
changes of pain intensity or muscle force in the exercis-
ing leg. Neither were there any significant changes in
muscle or plasma cytokine levels. Thus, 15 weeks of re-
sistance exercise twice per week did not influence the
peripheral release of cytokines.
Several studies have shown that exercise may have an
anti-inflammatory effect on various inflammatory condi-
tions, for example osteoarthritis of the knee [47, 48], by
reducing systemic cytokine levels [49]. Also, in FMS,
some previous studies, mainly from the same group, in-
dicate that an exercise intervention may reduce systemic
cytokine levels. Ortega and co-workers in a pilot study
of FMS patients reported that 4 months of aquatic exer-
cise three times per week reduced elevated serum IL-8
levels [50]. They later followed up on the study by show-
ing that after 8 months of aquatic exercise twice per
week there were no differences in the spontaneous and
lipopolysaccharide (LPS)-stimulated monocyte release of
IL-1β or IL-6 in FMS compared to healthy controls, but
a lower release of TNF and higher release of IL-10. At
baseline, before exercise, the release of all these cyto-
kines was higher in FMS [51]. Another study from the
group reported significantly reduced monocyte release of
IL-8 and noradrenaline in FMS after 8 months of aquatic
exercise compared to FMS patients that had not been
exercising [52]. Combined, these results indicate that an
exercise intervention may reduce systemic IL-8, but in-
crease IL-10. Available evidence from a systematic re-
view (mainly based on the studies above) suggests that
exercise interventions may reduce systemic IL-6 and IL-
8 levels [30]. Thus, these results differ from the results
of the present study regarding muscle levels of pro-
inflammatory cytokines. The results cannot be directly
compared as the previous studies investigated circulating
cytokine levels. However, plasma cytokine levels did not
Table 3 Static strength of the arm flexor and knee extensor muscles, and distance walked during a 6-min walk test (6MWT) in
patients with fibromyalgia (FMS) and healthy controls (CON) before and after 15 weeks of resistance exercise twice per week, as well
as the P value for within-group comparison (Wilcoxon test)
FMS P value CON P value
Before After Before After
Elbow flexion force (kg)
Right 11.9 (6.5)# 14.3 (6.7)* <0.001 18.4 (6.2) 16.9 (6.3) 0.845
Left 11.6 (7.3)# 14.2 (7.4)* 0.007 16.4 (5.9) 17.3 (4.3) 0.845
Knee extension force (N)
Right 322 (117) 340 (122) 0.153 380 (134) 406 (101) 0.248
Left 310 (108) 328 (138) 0.066 348 (125) 365 (106) 0.248
Most painful 307 (133)* 338 (110)* 0.307 380 (134) 405 (87) 0.248
6MWT (m) 561 (66) † 570 (100)# 0.153 633 (100) 665 (62) 0.054
Data are presented as median (interquartile range)
Bold italic figures denote significant differences
Between group comparisons: #P < 0.001, †P < 0.01 and *P < 0.05 (Mann-Whitney U test)
Table 4 Background data in 24 patients with fibromyalgia (FMS)
and 27 healthy controls (CON) obtained from questionnaires
and clinical examination, and significance level (P value) for
group comparison (Mann-Whitney U test)
Variables FMS CON P value
Age (years 57.0 (9.0) 57.0 (9.0) 0.800
Height (m) 1.65 (9.8) 1.65 (6.0) 0.743
Weight (kg) 68 (15) 63 (13) 0.091
BMI (kg/m2) 25.4 (6.6) 23.5 (4.5) 0.053
BP diastolic (mm Hg) 85 (10) 82.1 (8.3) 0.555
BP systolic (mm Hg) 133 (24) 131 (16) 0.494
Pain duration (years) 15.2 (8.2) NA
VAS overall (0–100) 52 (39) 0 (2) <0.001
Tender points (n) 15.9 (1.4) NA
PPT-all sites (kPa) 180 (112) 326 (100) <0.001
HAD-Depression (0–21) 6.0 (5.6) 1.6 (1.8) <0.001
HAD-Anxiety (0–21) 6.0 (7.0) 3.4 (3.1) 0.012
SF36-PSC (0–100) 30.0 (9.3) 54.4 (4.5) <0.001
SF36-MSC (0–100) 44.7 (18.5) 51.2 (6.0) 0.019
Data are presented as median (interquartile range)
Bold italic figures denote significant differences
BMI body mass index, BP blood pressure, HADS-Anxiety Hospital Anxiety and
Depression Scale—anxiety subscale, HADS-Depression Hospital Anxiety and
Depression Scale—depression subscale, NA not applicable, PPT-all sites
pressure pain thresholds (mean for all sites), SF36-PCS Short-Form Health
Survey 36-physical summary component, SF36-MSC Short-Form Health Survey
36-mental (psychological) summary component, VAS visual analogue scale
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change after the resistance exercise either. The reason
for this difference could be due to methodological issues;
for example, aquatic exercise compared to resistance ex-
ercise, duration of exercise, and so forth. The former
studies also included a limited number of patients (n <
14), which is why the power was probably low which
questions the validity of the results. Also, the present
study had a limited patient sample (n = 24), although
most other microdialysis studies studying muscle release
of biomarkers in chronic pain conditions have had simi-
lar sample sizes [17, 19–21]. However, it would be feas-
ible and warranted to conduct larger studies on the
effect of exercise on plasma levels of cytokines. In
addition, even if the results from the main study of this
randomized controlled trial showed a positive effect on
FMS symptoms [33], the pain and fatigue as well as
muscle force in the exercising leg were unaffected by the
resistance exercise. Thus, the exercise might also have
been of too low intensity to alter muscle cytokine levels.
Bjersing and co-workers measured serum and cerebro-
spinal fluid levels of biomarkers, among them IL-6 and
IL-8, before and after 15 weeks of Nordic walking in 49
FMS patients [31] and found no significant changes, in
line with the results of the present study. They further
did not find any effects of the exercise on 6MWT or
pain intensity.
In concordance with previous microdialysis studies
[29, 53] and biopsy studies [54, 55], the interstitial levels
of IL-6 and IL-8 increased in response to dynamic con-
tractions. Baseline levels of IL-6 and IL-8 were higher in
dialysate than in plasma, and the levels did not correlate.
This shows that IL-6 and IL-8 are released locally in the
muscle tissue. Indeed, both IL-6 and IL-8 are regarded
as myokines, i.e., cytokines that are released from
myocytes. Also, TNF increased in response to dynamic
contractions but only in CON. TNF is normally not
regarded as a myokine as it does not increase after exer-
cise, if not highly strenuous or prolonged [56]. The di-
alysate levels of TNF were lower than plasma levels,
which refutes that local release would have any effect on
plasma levels. Even if we cannot draw any conclusions
about plasma levels of cytokines in response to dynamic
contractions in this study, as they were only assessed be-
fore microdialysis, it is well known that plasma IL-6 in-
creases after exercise [27]. This is not related to muscle
damage, as shown also by low-intensity concentric con-
tractions leading to increased plasma IL-6 levels [27]. In
FMS, plasma and serum cytokine levels of IL-8 were re-
ported to be decreased after 45 min of moderate cycling
[29] and after an exhaustive treadmill exercise lasting
approximately 20 min [6]. The latter study also reported
increased serum IL-6 and TNF levels and a blunted re-
sponse of IL-10. The increase in IL-6 is in concordance
with the dialysate data in this study, but the results
regarding IL-8 differ. Other studies reported increased
gene expression of IL-10, but not IL-6 or TNF, up to 48 h
after a 25-min cycling exercise in FMS comorbid with
chronic fatigue syndrome [57], but no change in patients
with FMS only [58]. Hence, even if studies are not directly
comparable because of different methodologies, the diver-
ging results across studies make conclusions about the re-
lease of pro-inflammatory cytokines due to dynamic
contractions in FMS impossible at present.
The positive correlations between overall pain inten-
sity and muscle IL-6 may seemingly indicate a role for
cytokines in the local muscle pathophysiology of FMS.
On the contrary, the increased dialysate levels of IL-6
and IL-8 immediately after dynamic contractions did not
correlate with the increase in muscle pain or fatigue
levels at any visit, which speaks against this. Thus,
mechanisms other than muscle release of cytokines
probably account for the increase in pain and fatigue
during contractions. However, circulating cytokines, es-
pecially IL-8, released mainly from other sources may
still be involved in FMS pathology as has been reported
in many previous studies [59].
Few previous studies have explored muscle cytokine
levels with microdialysis. Of the pro-inflammatory cyto-
kines analyzed in this study, IL-1β in dialysate was de-
tectable in less than 50 % of samples and in very low
levels both in FMS and CON, whereas the other cyto-
kines were detectable in the majority of samples. This
shows that it is possible to recover cytokines from
muscle tissue with microdialysis even without adding
dextran or albumin, albeit this might have improved re-
covery [60, 61].
Insertion of the microdialysis catheter usually disrupts
the balance of substances in the tissue, which takes time
to normalize. For smaller molecules, such as serotonin,
glutamate and metabolites, 2 h of stabilization has been
shown to be sufficient in intramuscular microdialysis
[17]. For cytokines the pattern may be different. One
study reported about 30 % increases in IL-6 and IL-8
levels 6 h after insertion of a microdialysis catheter in
the vastus lateralis muscle of healthy volunteers [62].
Also, for IL-6 and IL-8 in this study there was a general
tendency to an increase in muscle levels with time. This
could, of course, also be an effect of the dynamic con-
tractions, as an increased release of both these cytokines
was found in the dialysate sample obtained directly after
the contractions. However, this was a transient increase
and in the following sample the levels did not differ
from baseline. Nevertheless, it is not known if a steady
state is reached even after 6 h so it might not be feasible
in a clinical situation to prolong the microdialysis to
reach a steady state.
The strength of the present study is that the local re-
lease of cytokines was measured (with microdialysis) in a
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muscle (vastus lateralis) that had been subjected to resist-
ance exercise twice per week for 15 weeks. The microdial-
ysis method also allows continuous measurements in
response to, for example, muscle contractions, as in the
present study. No previous studies have made similar at-
tempts, even if biopsy studies before and after acute exer-
cise have been performed [54, 55]. Another strength is
that the study population represents FMS patients in the
general population and not patients from tertiary care
clinics. This may explain why the depression levels were
within the normal range, contrary to other studies in FMS
[63]. Among the study limitations is the sample size. Even
if it was larger than previous studies regarding exercise ef-
fects on cytokine levels in FMS [50–52], the sample was
still somewhat limited. Furthermore, to be able to com-
pare cytokine levels before and after the intervention, the
average of the dialysate levels during the dynamic contrac-
tions was used. This might have disguised subtle changes
between sessions. However, as shown in Fig. 1, the levels
of the cytokines showed a similar pattern at both sessions
which why this is less likely. No attempts were made to
match the groups for variables other than age. One can
therefore argue that any changes in outcome measures
could be due to improvement in physical activity in FMS
that was without significance for the pathophysiology.
However, participants in both groups were physically in-
active, and volunteered to participate as they wanted to
start exercising. Finally, only pro-inflammatory cytokines
were analyzed. Due to the recent findings of reduced IL-
10 in response to exercise it would have been interesting
to also analyze IL-10 and other anti-inflammatory cyto-
kines such as IL-4 and IL-13.
Conclusion
Although 15 weeks of progressive resistance exercise im-
proved arm muscle force and reduced overall pain in FMS
it neither altered the muscle levels of IL-1β, IL-6, IL-8, or
TNF, nor pain and fatigue levels in the vastus lateralis
muscle. However, TNF was lower in FMS than CON and
increased during dynamic contractions only in CON.
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